BRIEF — WuXi chooses Ireland for first manufacturing site outside China

Ireland has been chosen as the location of the first manufacturing site outside of China of WuXi Biologics (HK: 2269).

The Hong Kong-listed global open-access biologics technology platform company is set to invest $392 million in building a new biologics drug substance manufacturing facility.

Single-use bioreactors for commercial biomanufacturing will be used at the site in Dundalk, close to the border with Northern Ireland.

This facility will create approximately 700 jobs during its construction and more than 400 highly-skilled jobs after establishment over five years.